IP Library Granted Patent US 6,951,640
Granted Patent B2
US 6,951,640 · App. 10/375,454 · Granted Oct 4, 2005

Use of novel metalloporphyrins as imageable tumor-targeting agents for radiation therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,951,640
App. No.
10/375,454
Granted
Oct 4, 2005
Kind
B2
Abstract

The present invention covers halogenated derivatives of boronated phorphyrins containing multiple carborane cages having the formula which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these halogenated derivatives of boronated porphyrins in tumor imaging and cancer treatment.

Claims (18)

1. A method of tumor imaging using single-photon-emission tomography(SPECT) wherein the tumor imaging agent administered to the subject is a pharmaceutically acceptable composition containing a compound of the formula

wherein M is a SPECT imageable radiometal with or without another carrier metal, R is selected from the group consisting of hydrogen, a halogen, a halogen isotope, or a nitro group, with at least one R being a halogen, a halogen isotope or a nitro group, and Y is selected from the group consisting of ortho, meta, or para O(CH 2 ) n C 2 HB 9 H 10 or O(CH 2 ) n C 2 HB 10 H 10 wherein, 0≦n≦20 and C 2 HB 9 H 10 is nido ortho, meta- or para-carborane and C 2 HB 10 H 10 is ortho-carborane, meta-carborane para-carborane.

2. The method of claim 1 , wherein at least one R is a halogen radioisotope.

3. The method of claim 2 wherein the halogen radio isotope is selected from the group consisting of 77 Br, 123 I, 125 I, 131 I, 209 At, 210 At, or 211 At.

4. The method of claim 1 , wherein M is selected from the group consisting of 67 Cu, 99m Tc, and 111 In.

5. A method of tumor imaging using positron emission tomography (PET) wherein the tumor imaging agent administered to the subject is a pharmaceutically acceptable composition containing a compound of the formula

wherein M is a PET imageable radiometal with or without another carrier metal, R is selected from the group consisting of hydrogen, a halogen, a halogen isotope, or a nitro group, with at least one R being a halogen, a halogen isotope or a nitro group, and Y is selected from the group consisting of ortho, meta, or para O(CH 2 ) n C 2 HB 9 H 10 or 0 (CH 2 ) n C 2 HB 10 H 10 wherein, 0≦n≦20 and C 2 HB 9 H 10 is nido ortho, meta-or para carborane and C 2 HB 10 H 10 is ortho-carborane, meta-carborane or para-carborane.

6. The method of claim 5 wherein M is 64 Cu.

7. The method of claim 5 wherein at least one R is a halogen radioisotope.

8. The method of claim 7 wherein the halogen radioisotope is selected from the group consisting of 18 F, 76 B, 124 I, 209 At, 210 At, and 211 At.

9. A method of cancer treatment comprising:

administering tumor targeting agent to the subject, wherein the tumor targeting agent is a pharmaceutically acceptable composition containing a compound of the formula

wherein M is a single-photon-emission tomography imageable radiometal or a paramagnetic metal, R is selected from the group consisting of hydrogen, a halogen, a halogen isotope, or a nitro group, with at least one R being a halogen, a halogen isotope or a nitro group, and Y is selected from the group consisting of ortho, meta, or para O(CH 2 ) n C 2 HB 9 H 10 or O(CH 2 ) n C 2 HB 10 H 10 wherein, 0≦n≦20 and C 2 HB 9 H 10 is nido ortho, meta- or para-carborane and C 2 HB 10 H 10 is ortho-carborane, meta-carborane or para-carborane; and

subsequently irradiating the tumor.

10. The method of claim 9 wherein R is bromine, a bromine isotope, iodine, an iodine isotope, chlorine, a chlorine isotope, fluorine, a fluorine isotope, astatine, an astatine isotope, a nitro group, a combination thereof, or a combination thereof that includes hydrogen.

11. The method of claim 9 wherein M is selected from the group consisting of vanadium (V), manganese (Mn), iron (Fe), ruthenium (Ru), technetium (Tc), chromium (Cr), platinum (Pt), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn),germanium (Ge), indium (In), tin (Sn), yttrium (Y), gold (Au), barium (Ba), tungsten (W), and gadolinium (Gd).

12. The method of claim 9 wherein the tumor is irradiated with thermalized neutrons for boron neutron capture therapy cancer treatment.

13. The method of claim 9 wherein the tumor is irradiated with a beam of red laser light for photodynamic therapy cancer treatment.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 7, 2003
From: BROOKHAVEN SCIENCE ASSOCIATES
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 014236/0952 →